Loading...
Surveys of postmenopausal women show that most with dyspareunia arising from vulvovaginal atrophy (VVA) do not find vaginal lubricants and moisturizers to be helpful; also, many are concerned about the safety of estrogen treatment (the most effective local therapy). Thus, development of new vaginal treatment options would be beneficial. In a trial of dehydroepiandrosterone (DHEA), 255 women with VVA were randomized to receive a daily vaginal suppository containing DHEA (3.25 mg or 6.5 mg) or no DHEA (placebo) for 12 weeks. Participants recorded the extent of their dyspareunia and other symptoms.
At 12 weeks, dyspareunia severity scores decreased from baseline by 34% and 52% in the placebo and 6.5-mg DHEA groups, respectively (P=0.013). Vagin…